TrialJournal for immunotherapy of cancer2020

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.

Lin Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.